Institutional Confidence Builds in Abivax Ahead of Key Clinical Catalysts

Jefferies Financial Group acquires a major stake in Abivax SA as the biotech firm nears pivotal Phase 3 trial results for ulcerative colitis and Crohn's disease treatments.

A major institutional investor has taken a significant stake in Abivax SA, signaling strong belief in the biotechnology firm's upcoming clinical milestones. Jefferies Financial Group recently acquired a $38.8 million equity position in the company, a move that highlights growing institutional interest as critical trial data readouts approach.

Strategic Investment Timing

Jefferies purchased 457,325 shares, giving the bank approximately 0.59% of the company's voting rights. This investment is part of a broader trend of portfolio adjustments by other market participants. For instance, Millennium Management increased its holding by 6.0% during the first quarter of this period, while entities like Octagon Capital have also recently modified their positions.

The timing of these investments is strategically aligned with Abivax's clinical development calendar. The market anticipates topline results from the Phase 3 ABTECT maintenance study in ulcerative colitis by the end of the second quarter of 2026. These results are considered fundamental for the planned New Drug Application submission to the U.S. Food and Drug Administration, which management has targeted for late 2026.

Parallel Clinical Pathways and Financial Health

Concurrently, the company is advancing its ENHANCE-CD study in Crohn's disease, with initial data expected in late 2026. The coming months are therefore pivotal for validating the clinical promise of the company's lead candidate, obefazimod.

Investor attention will also focus on the full financial results for fiscal year 2025, scheduled for release on March 23. According to current company statements, Abivax's liquidity is secured through the fourth quarter of 2027. This financial runway is intended to support the operational execution of upcoming milestones and preparations for a potential commercial launch. The year-end report will provide a detailed update on the cash burn rate and the precise timeline for the forthcoming FDA regulatory process.